Analysis of the gene expression dataset from the TARGET study revealed that high expression of both ALDH1A2 and ALDH1A3 was associated with a worst outcome for neuroblastoma patients (n= 33/135 and 72/135 for ALDH1A2 and ALDH1A3 respectively; Figures 7C and D). The gene discussed is ALDH1A2; the disease is neuroblastoma.